Patents by Inventor Christopher K. Glass

Christopher K. Glass has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MODULATION OF ENHANCER RNA MEDIATED GENE EXPRESSION
    Publication number: 20190040386
    Abstract: Disclosed herein are methods and compounds for inhibiting gene expression by inhibiting enhancer RNAs (eRNAs). Such methods and compounds are useful for reducing expression of certain genes, many of which are associated with a variety of diseases and disorders.
    Type: Application
    Filed: July 11, 2018
    Publication date: February 7, 2019
    Applicants: Ionis Pharmaceuticals, Inc., The Regents of the University of California
    Inventors: Susan M. Freier, Christopher K. Glass, Michael G. Rosenfeld, Wenbo Li, Michael Tun Yin Lam
  • MODULATION OF ENHANCER RNA MEDIATED GENE EXPRESSION
    Publication number: 20170226506
    Abstract: Disclosed herein are methods and compounds for inhibiting gene expression by inhibiting enhancer RNAs (eRNAs). Such methods and compounds are useful for reducing expression of certain genes, many of which are associated with a variety of diseases and disorders.
    Type: Application
    Filed: October 3, 2016
    Publication date: August 10, 2017
    Applicants: Ionis Pharmaceuticals, Inc., The Regents of the University of California
    Inventors: Susan M. Freier, Christopher K. Glass, Michael G. Rosenfeld, Wenbo Li, Michael Tun Yin Lam
  • Modulation of enhancer RNA mediated gene expression
    Patent number: 9518261
    Abstract: Disclosed herein are methods and compounds for inhibiting gene expression by inhibiting enhancer RNAs (eRNAs). Such methods and compounds are useful for reducing expression of certain genes, many of which are associated with a variety of diseases and disorders.
    Type: Grant
    Filed: May 22, 2013
    Date of Patent: December 13, 2016
    Assignees: Ionis Pharmaceuticals, Inc., The Regents of the University of California
    Inventors: Susan M. Freier, Christopher K. Glass, Michael G. Rosenfeld, Wenbo Li, Michael T. Lam
  • MODULATION OF ENHANCER RNA MEDIATED GENE EXPRESSION
    Publication number: 20150176005
    Abstract: Disclosed herein are methods and compounds for inhibiting gene expression by inhibiting enhancer RNAs (eRNAs). Such methods and compounds are useful for reducing expression of certain genes, many of which are associated with a variety of diseases and disorders.
    Type: Application
    Filed: May 22, 2013
    Publication date: June 25, 2015
    Applicants: The Regents of the University of California, Isis Pharmaceuticals, Inc.
    Inventors: Susan M. Freier, Christopher K. Glass, Michael G. Rosenfeld, Wenbo Li, Michael T. Lam
  • Identification of an evolutionarily conserved pathway mediating transrepression of inflammatory response genes by nuclear receptors
    Patent number: 8241863
    Abstract: The present invention relates to a method of screening for a compound that regulate SUMOylation of the nuclear receptor proteins comprising contacting the compound of interest to the nuclear receptor protein, and detecting SUMOylation of the nuclear receptor protein, thereby screening for a compound that regulates SUMOylation.
    Type: Grant
    Filed: March 10, 2006
    Date of Patent: August 14, 2012
    Assignee: The Regents of the University of California
    Inventors: Gabriel Pascual, Christopher K. Glass, Michael G. Rosenfeld
  • IDENTIFICATION OF NEUROPROTECTIVE AGENTS USING PRO-INFLAMMATORY HUMAN GLIAL CELLS
    Publication number: 20120003655
    Abstract: Provided herein are methods for, inter alia, identifying new therapeutic agents using human cell-based models.
    Type: Application
    Filed: December 3, 2009
    Publication date: January 5, 2012
    Applicant: The Salk Institute for Biological Studies
    Inventors: Maria C.N. Marchetto, Fred H. Gage, Christopher K. Glass, Kaoru Saijo, Beate Winner
  • Compounds that Prevent Macrophage Apoptosis and Uses Thereof
    Publication number: 20090111786
    Abstract: The present invention relates to microbial infection, and in particular, the reduction of apoptosis associated with microbial infection, the screening of Liver X Receptor agonist and/or Retinoid X Receptor agonist that reduce apoptosis, and the treatment and analysis of microbial infection in vivo. In one embodiment, the present invention relates to Liver X Receptor agonist and/or Retinoid X Receptor agonist including but not limited to an agonist increasing the activity of Liver X Receptor and/or Retinoid X Receptor.
    Type: Application
    Filed: December 2, 2005
    Publication date: April 30, 2009
    Inventors: Christopher K. Glass, Annabel E. Valledor, Michael Karin, Li-Chung Hsu
  • Identification of an Evolutionarily Conserved Pathway Mediating Transrepression of Inflammatory Response Genes by Nuclear Receptors
    Publication number: 20080182778
    Abstract: The present invention relates to a method of screening for a compound that regulate SUMOylation of the nuclear receptor proteins comprising contacting the compound of interest to the nuclear receptor protein, and detecting SUMOylation of the nuclear receptor protein, thereby screening for a compound that regulates SUMOylation.
    Type: Application
    Filed: March 10, 2006
    Publication date: July 31, 2008
    Inventors: Gabriel Pascual, Christopher K. Glass, Michael G. Rosenfeld
  • Transcription factor coactivator protein, p/CIP
    Patent number: 7211402
    Abstract: The present invention provides a substantially purified nucleic acid molecule encoding a p/CIP polypeptide, which regulates the activity of CBP/p300-dependent transcription factors. The invention also provides a substantially purified p-CIP polypeptide and active fragments thereof. In addition, the invention provides methods of identifying an effective agent that alters the association of a p/CIP polypeptide with a second protein. Further provided herein are methods of selectively inhibiting signal transduction pathways using an active fragment of a p/CIP polypeptide or a nucleic acid molecule encoding such an acive fragment.
    Type: Grant
    Filed: October 21, 2004
    Date of Patent: May 1, 2007
    Assignee: The Regents of the University of California
    Inventors: Michael G. Rosenfeld, Christopher K. Glass, David W. Rose, Joseph Torchia
  • Transcription factor coactivator protein, p/CIP
    Patent number: 6812336
    Abstract: The present invention provides a substantially purified nucleic acid molecule encoding p/CIP, which regulates the activity of CBP/p300 dependent transcription factors. The invention also provides substantially purified p/CIP and peptide portions of p/CIP. The invention also provides methods of selectively inhibiting signal transduction pathways using a peptide portion of p/CIP or a nucleic acid molecule encoding such a peptide portion.
    Type: Grant
    Filed: May 5, 2000
    Date of Patent: November 2, 2004
    Assignee: The Regents of the University of California
    Inventors: Michael G. Rosenfeld, Christopher K. Glass, David W. Rose, Joseph Torchia